Objective: Our goal was to describe the prospective risk and timing of symptomatic hemorrhage in a large cohort of followed patients with intracerebral cavernous malformations (ICMs).
The prospective hemorrhage rate in patients with intracerebral cavernous malformations (ICMs) has been estimated to be 0.7%-4.2% in existing case series. 1 Studies have been difficult to directly compare because of methodologic differences and small numbers of patients. Retrospective calculations assume a constant risk of hemorrhage since birth and therefore may not be accurate because ICMs are more likely thought to be acquired, rather than congenital. Prospective hemorrhage rates are clearly more accurate, but the definition of hemorrhage in prospective studies differs. Some use overt, extralesional hemorrhage, whereas some include hemorrhage with or without clinical correlation. Studies also differ in the method of hemorrhage rate, with some using person-years and others using lesion-years. In addition to differences in calculating hemorrhage rates, other differences include limiting the population to brainstem location or just familial forms.
Risk factors for prospective hemorrhage uniformly include prior hemorrhage, but other risk factors vary from study to study. The impact of sex, ICM location, and multiple lesions has been debated. Many of these case series are small or limited in follow-up.
Our objective was to determine the prospective hemorrhage risk in a large cohort of patients and determine timing to first as well as subsequent hemorrhages.
METHODS Patient selection.
The records of all patients seen at our institution between 1989 and 1999 with the radiographic diagnosis (MRI) of cavernous malformation were retrospectively identified.
Data collection. The primary investigator reviewed all medical records. Extensive demographic and clinical information was abstracted from medical records on a standardized form and entered into a computerized database. Demographic information, medical history, initial presentation, and treatment were recorded.
Follow-up information was calculated from time of first diagnosis to most recent contact. Follow-up information was obtained between 2000 and 2003 from the medical record if the patient seen at our institution within 6 months of our review. If he or she did not follow up at our institution, a mail survey was sent and followed by a phone call and ascertainment of medical records and films from other medical institutions. Follow-up information obtained included pregnancy since diagnosis, surgery or radiosurgery since diagnosis, and the occurrence of a symptomatic hemorrhage due to ICM. A definitive prospective hemorrhage was defined as a new clinical event (focal deficit, seizure, or severe headache) in association with radiographic evidence of acute hemorrhage or autopsy data suggesting acute hemorrhage. A probable prospective hemorrhage was defined as a clinical event with medical records obtained from a medical institution outside of our medical record system suggesting intracerebral hemorrhage, but no films for us to personally review. An undocumented prospective hemorrhage was defined as an acute clinical event, but no imaging report or films to personally review. Typically, the latter was information obtained from the patient only without verification by medical records. This diagnosis of definitive hemorrhage is similar to that described as an overt hemorrhage by Moriarity et al. 2 and a type 1 lesion by Zabramski et al.
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Radiographic data. Initial brain MRI scans were reviewed by the primary investigator. The imaging study closest to the time of diagnosis was reviewed in detail. ICMs were identified as described previously. 3, 4 Cryptic vascular malformations that could not be clearly labeled as ICM were excluded (n ϭ 37).
Location and diameter were recorded for each ICM. Association with a venous angioma or other vascular malformation was also recorded. In addition, the type of ICM was recorded based on the nomenclature by Zabramski et al. 3 Multiplicity was noted. When multiple ICMs were present, the location and size of symptomatic lesions were recorded in addition to 4 additional lesions. The symptomatic lesion was included in analysis of variables determining future hemorrhage. If there were multiple lesions and no symptomatic lesion, the largest was used.
Follow-up brain MRI scans were reviewed when available. If patient presented with a new focal deficit and an MRI scan was done at the time, this was reviewed to confirm the presence of acute or subacute hemorrhage.
Standard protocol approvals, registrations, and patient consents. We received approval from the neurology research committee and institutional review board. Informed consent was obtained from all patients participating in the study.
Statistical analysis. Descriptive statistics including means,
SDs, and frequencies were used for patient characteristics and presenting symptoms. Comparison of proportions was performed with the Fisher exact test with significance at p Ͻ 0.05. The Kaplan-Meier method was used to determine survival free of prospective hemorrhage. The prospective hemorrhage rate was determined based on the number of definitive and probable hemorrhages during the follow-up period divided by the number of prospective person-years of follow-up (an incidence rate); the annual rates presented are percent per person-year. Patients were censored from this calculation if they underwent complete surgical removal of the ICM, but not if they underwent gamma knife therapy. Predictive factors for prospective hemorrhage were evaluated using multivariable Cox proportional hazards modeling with a p Ͻ 0.05. Predictors evaluated included age, gender, presentation with hemorrhage, ICM location, use of antithrombotics, multiplicity of ICM, venous angioma, ICM size, and ICM type.
RESULTS
A total of 292 patients were identified (47.3% male). The mean age at diagnosis was 45.8 years (range 3.5-88.9 years). Demographic features of this group are noted in table 1. Of the patients, 182 (62%) presented to medical attention with symptoms related to the cavernous malformation, 15 (5%) presented with symptoms of unclear relationship to the ICM and in 95 patients (33%) the ICM was an incidental finding. Of those with symptoms related to the ICM, 74 patients presented with radiographic evidence of acute hemorrhage. Hemorrhage due to the ICM was heralded most commonly by focal deficits (n ϭ 40), but patients also presented with seizure related to the hemorrhage (n ϭ 15), headache without focal deficit (n ϭ 13), and neurologic symptoms without focal neurologic deficit (n ϭ 6). An additional 76 patients presented with seizure without associated radiographic evidence of an acute overt hemorrhage, 19 patients presented with a focal neurologic deficit without overt hemorrhage, and 13 presented with neurologic symptoms without objective clinical deficit or overt hemorrhage. Most commonly the latter included diplopia, vertigo, and headache. All patients had an MRI scan, and 88% of patients had films that were available for review by the primary author. More than 75% of patients had an MRI scan that was within 1 year of the initial diagnosis, with the majority being within 6 months of diagnosis. Of the patients, 236 (81%) had multiple brain imaging studies performed over time. Radiographically, 237 (82%) of patients had a single cavernous malformation (CM), and 55 (18%) had multiple CMs. In patients with multiple lesions, 34 had between 2 and 4 lesions; however, the additional patients had from 5 lesions to more lesions than were able to be counted. The location, type, and association with venous angiomas are noted in table 2.
The median length of follow-up was 7.3 years (range 0 -25 years; 2,035 person-years). The median length of follow-up for the symptomatic patients was 7.8 years and for the asymptomatic patients or patients with symptoms of unclear relationship was 5.7 years. Fifteen (5.1%) patients did not have follow-up greater than 6 months, and 65 (22.3%) did not have follow-up greater than 5 years. Thirty-three patients had died at the last follow-up time. Sixty-eight patients underwent surgical excision, and 10 underwent gamma knife therapy as a first procedure. One patient underwent surgical excision after gamma knife failure, and 5 underwent surgical excision a second time (reoperation of prior CM or surgical excision of second CM). One patient underwent gamma knife therapy after surgery.
Thirty-two patients (16%) had a prospective symptomatic hemorrhage after their initial presentation (20 definite, 8 probable, and 4 undocumented; see Methods). All patients had clinical symptoms associated with the hemorrhage. The highest rate of hemorrhage was identified in those who initially presented with hemorrhage, followed by those with symptoms not related to hemorrhage, and finally those with symptoms that were incidental or in whom the symptoms were of unclear relationship to the lesion (table 3). In the patients initially presenting with hemorrhage, the risk declined after the first 2 years. The median time from hemorrhage at diagnosis to second hemorrhage was 8 months (2.3-30.9 months). Of the patients, 81% were free of prospective hemorrhage at 10.6 years.
Of the 32 patients with prospective symptomatic hemorrhage, 19 (59%) initially presented with hemorrhage. Univariate analysis of risk factors for pro- Abbreviation: CM ϭ cavernous malformation. a Note in patients with multiple lesions, the symptomatic lesion was used to characterize location and type. If there was no symptomatic lesion, the largest was used. ; p Ͻ 0.001). Pregnancy was not found to be a risk factor. Of the 154 female patients, 105 had pregnancies before the diagnosis, and 12 women had pregnancies after the diagnosis of ICM. Of those 12 patients, none had symptoms during pregnancy. Nine patients had 2 or more symptomatic hemorrhages after their initial diagnosis: 4 patients had 2 hemorrhages, 3 patients had 3, and 2 patients had 4 or more hemorrhages after diagnosis. For 8 of the 9 patients, the second event occurred within 2.75 years of the first event with 5 of the 9 within the first year. Because of the few multiple recurrent hemorrhages, risk factors could not be well assessed. DISCUSSION The annual risk of hemorrhage stratified by initial presenting symptom is useful to the clinician and patient. In addition, these numbers can be compared with the risk of intervention to determine appropriate therapy. The annual risk of hemorrhage is very low in patients in whom the ICM is an incidental finding. In patients with prior hemorrhage, the risk is initially high but decreases over time.
Timing to first hemorrhage and subsequent hemorrhages has been a subject of interest. Prior small case series have noted an apparent temporal clustering of hemorrhages in patients with ICM. [5] [6] [7] Our data also suggest a decline in hemorrhage rate over time in patients initially presenting with hemorrhage. This can be important for patient counseling and important when the natural history is compared with to the risk/benefit ratio of potential treatments such as surgery and radiosurgery. It has been suggested that radiosurgery may reduce the risk of recurrent hemorrhage after 2 years; however, it is also possible this reduction is due to the natural history of the lesion.
Prior hemorrhage as a risk factor has been clearcut in multiple studies. 1 However, multiplicity has been found to be a risk factor for future hemorrhage in few, 8 but not all, prospective studies. 9 -11 Multiple lesions are most common in the familial form of ICM, and it has been suggested that the familial form is more aggressive. 8 The risk is not multiplicative by the number of lesions but does increase the risk at least 2-fold.
Contrasting other studies, 2,9,12 we found that male gender increased the risk of future hemorrhage. It is not clear that there is a biologic reason for this, and more likely this increase was due to chance. In addition, contrasting some studies, 12 we did not find pregnancy to be a risk factor for hemorrhage.
This study is limited by retrospective data identification of patients and its inherent biases. Tertiary referral bias is present in the study and may overestimate severity of outcome. However, because of the low incidence of ICM, we did not exclude referral patients. In addition, ascertainment of prospective hemorrhages was limited to those who returned to our institution or filled out a survey. Fifteen patients (5.1%) did not have follow-up greater than 6 months. Therefore, it is possible that the number of hemorrhages was higher than reported. In addition, more than 20% of patients did not have follow-up longer than 5 years, limiting the long-term applicability of this study.
Although certain risk factors for recurrent hemorrhage in patients for ICM have been determined, modifiable risk factors have not been found. It will be important in the future to develop registries of patients to increase the ability to detect risk factors in addition to standardizing definitions of hemorrhage and radiographic features of ICM. 13 In addition, advancing genetic data and neuroimaging 14 will undoubtedly improve our understanding of ICM.
This study provides a useful estimate of prospective annual symptomatic hemorrhage risk in patients with ICM stratified by presentation. It confirms that prior hemorrhage is the greatest risk for future hemorrhage and suggests multiplicity as a risk factor. Symptomatic hemorrhage risk tends to decrease with time in patients initially presenting with hemorrhage.
Vote for Your Favorite Neuro Film Festival Entry by March 8
The entries for the 2012 Neuro Film Festival ® are in and public voting for "Fan Favorite" has begun. The event highlights inspiring stories from patients and their families and caregivers about living with a neurologic condition to help raise awareness about the need for more research to cure brain disease. The Grand Prize is $1,000 and a trip to New Orleans. Vote online now at www.neurofilmfestival.com.
